 

Active ingredient: Acetaminophen; Butalbital 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 

 

Acetaminophen; Butalbital Tablets are a DESI1 effective drug for which there are no 
known or suspected bioequivalence problems, and as such is rated “AA” in the 
FDA/CDER’s Approved Drug Products with Therapeutic Equivalence Evaluations 
(“Orange Book”). 

________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Not Applicable 

 

Bioequivalence based on (90% CI): Not Applicable 

 

Waiver request of in-vivo testing: 325 mg/50 mg and 650 mg/50 mg pursuant to 21 
CFR 320.22(c) provided that the in-vitro dissolution profiles of the proposed product are 
comparable to those of the reference product. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD 
website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the 
dissolution information for this product at this website. Please conduct comparative 
dissolution testing on 12 dosage units each of all strengths of the test and reference 
products. Specifications will be determined upon review of the application. 

 

 

_______________________________ 

1 Drug Efficacy Study Implementation 


